{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Keros Therapeutics, Inc.
Keros Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Market Challenges
Keros Therapeutics, Inc. has recently adjusted its valuation, with a P/E ratio of 145 and a price-to-book value of 0.84. Despite a recent stock price increase, the company has experienced significant declines over the past year and three years, contrasting sharply with broader market performance and its peers.
Is Keros Therapeutics, Inc. overvalued or undervalued?
As of October 17, 2025, Keros Therapeutics, Inc. is considered fairly valued despite a high P/E ratio of 145 and a PEG ratio of 1.42, indicating potential overvaluation, especially as it has underperformed the S&P 500 with a 1-year return of -77.36%.
Keros Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges
Keros Therapeutics, Inc. has experienced a valuation adjustment, reflected in its high P/E ratio of 145 and a price-to-book value of 0.84. Despite facing significant stock declines over the past year, the company remains notable for its elevated valuation compared to peers in the Pharmaceuticals & Biotechnology sector.
Is Keros Therapeutics, Inc. overvalued or undervalued?
As of October 17, 2025, Keros Therapeutics, Inc. is considered overvalued with a high P/E ratio of 145 and a PEG ratio of 1.42, indicating limited growth potential relative to its price, especially when compared to peers with negative P/E ratios.
Is Keros Therapeutics, Inc. overvalued or undervalued?
As of October 17, 2025, Keros Therapeutics, Inc. is considered overvalued with a high P/E ratio of 145 and a one-year return of -77.36%, indicating a shift from a very attractive to a fair valuation grade.
Keros Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout
Keros Therapeutics, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. Technical indicators present a mixed outlook, with bullish daily moving averages contrasted by bearish monthly trends. Despite a challenging year, the stock has shown short-term resilience, suggesting renewed investor interest.
Is Keros Therapeutics, Inc. technically bullish or bearish?
As of August 13, 2025, Keros Therapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, having outperformed the S&P 500 recently but significantly underperformed over the past year.
Is Keros Therapeutics, Inc. overvalued or undervalued?
As of August 13, 2025, Keros Therapeutics, Inc. is considered overvalued with a high P/E ratio of 145 and a one-year return of -71.21%, indicating a shift from attractive to fair valuation compared to its peers and the S&P 500.
Is Keros Therapeutics, Inc. overvalued or undervalued?
As of May 6, 2025, Keros Therapeutics, Inc. is considered undervalued with an attractive valuation grade despite a high P/E ratio of 145, a Price to Book Value of 0.84, and a favorable PEG ratio of 1.42, although it has underperformed the S&P 500 with a 1-year return of -70.37%.
Is Keros Therapeutics, Inc. technically bullish or bearish?
As of June 9, 2025, Keros Therapeutics, Inc. shows a bearish trend due to daily moving averages and monthly indicators, despite some bullish signals on the weekly timeframe.
Who are in the management team of Keros Therapeutics, Inc.?
As of March 2022, Keros Therapeutics, Inc.'s management team includes Dr. Jasbir Seehra as CEO and Director, along with Independent Directors Dr. Mary Gray, Mr. Nima Farzan, Mr. Carl Gordon, Mr. Tomer Kariv, and Mr. Julius Knowles.
What does Keros Therapeutics, Inc. do?
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for hematological and musculoskeletal disorders. As of March 2025, it reported net sales of $211 million and a market cap of $546.68 million.
How big is Keros Therapeutics, Inc.?
As of Jun 18, Keros Therapeutics, Inc. has a market capitalization of 546.68 million, with net sales of 214.72 million and a net profit of 4.20 million over the latest four quarters. The company reported shareholder's funds of 571.55 million and total assets of 615.89 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
